Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
NCT01144338 on ClinicalTrials.gov · last registry update 2018-08-08
An unusually large phase 3: 14,752 participants, more than double the 424 typical for the stage. The sponsor logged completion for 21 April 2017. Primary outcome, as filed: Primary Efficacy Outcome MACE Events. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 14,752
- Started
- 2010-06-18
- Primary completion
- 2017-04-21 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Primary Efficacy Outcome MACE Events
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.